Navigation Links
Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival,Benefits as Mitigator Against Radiation-Induced Damage in Study

itting Protectan CBLB502 to the Department of Defense (DoD) in response to a recently published Request for Proposal (RFP) for medical radiation countermeasures to treat gastrointestinal effects of acute radiation syndrome. The RFP award would provide funding for development of the countermeasure through FDA approval, as well as a commitment to purchase up to 500,000 doses, thereafter.

Protectan CBLB502 is undergoing an accelerated development program under the FDA two-animal rule, which requires the Company to show efficacy in two animal species and only safety in humans. Cleveland BioLabs is in the process of completing Good Manufacturing Practices compliant (cGMP) manufacturing of Protectan CBLB502 and plans to submit an Investigational New Drug (IND) application for a human safety study later this year.

Cleveland BioLabs President and Chief Executive Officer, Michael Fonstein, Ph.D., added, "The radio-protective properties of Protectan CBLB502 are specific to healthy, non-cancerous tissues, making CBLB502 a promising candidate to treat side effects of cancer patients undergoing radiation therapy and potentially, chemotherapy. The National Cancer Institute reports that for every $1 spent on cancer treatments, approximately $0.70 is spent on supportive care to counteract the side effects of treatment. We believe this could be a significant potential follow-on market for CBLB502."

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com.
'"/>




Page: 1 2 3

Related medicine technology :

1. Cholesterol Drug Fails to Slow Progression of Coronary Disease, Cleveland Clinic Study Reports
2. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
7. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
8. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
9. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
10. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
(Date:9/30/2014)... 2014 The Chinese wound care market is ... in the incidence of lifestyle diseases, coupled with the ... of better quality of wound care products provide the ... of public health insurance schemes and increased reimbursement rate ... on the findings of primary and secondary researches, this ...
(Date:9/30/2014)... BRUNSWICK, N.J., Sept. 30, 2014 The ... Kessler Foundation and New Jersey Health Foundation (NJHF) ... and patient care programs has been announced by ... officer of Kessler Foundation and James M. ... "The experience of New Jersey Health ...
(Date:9/30/2014)... Calif. , Sept. 30, 2014 ... of the American Association of Tissue Banks (AATB), ... , Chief Executive Officer. Accreditation follows ... by a specially trained AATB inspector.  It establishes ... performance within the facility meets or exceeds the ...
Breaking Medicine Technology:China Wound Care Market 2China Wound Care Market 3Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Biostructures, LLC Earns AATB Accreditation 2
... 2007 - Late-breaking Phase III,clinical trial data ... Thrombosis and Haemostasis (ISTH) Congress demonstrate,that once-daily ... venous thromboembolism (VTE) in patients undergoing,knee replacement ... current standard of care. Patients in the ...
... with Positive Phase IIa Clinical,Trial Results, First ... Key,Product in AM-Pharma's Pipeline , BUNNIK, The ... developing novel therapeutics to treat,infectious and inflammatory ... its Phase IIa Alkaline Phosphatase (AP) trial,for ...
Cached Medicine Technology:Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5
(Date:10/1/2014)... October 01, 2014 Two bicyclists began ... them across the country in an effort to raise ... families. The cyclists, a father-daughter team, plan to ... in Blaine, Washington and finishing in Key West Florida. ... For The Warriors®, a national nonprofit organization that assists ...
(Date:10/1/2014)... Long-acting insulin is safer and more effective than ... according to new research published in the ... and twice-daily doses of both long- and intermediate-acting ... , "In patients with Type 1 diabetes, we ... insulin when it came to controlling blood sugar, ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Indosoft, Inc., a ... Q-Suite, announces that it has added support for Sangoma ... Sangoma and Indosoft have a history of bringing ... Sangoma's patent-pending technology offers a significant benefit to those using ... that is now available to users of Q-Suite. , In ...
(Date:10/1/2014)... October 01, 2014 Nearly a year-and-a-half ... Pueblo County District Court jury awarded him $4.75 million; ... 61 years old. Casper had been too sick ... , According to the Court Documents (District Court, Pueblo ... BPH, a benign non-cancerous condition of his prostate, when ...
(Date:9/30/2014)... Thompson HealthDay Reporter TUESDAY, ... of Ebola has surfaced in the United States, involving a ... announced late Tuesday. The critically ill patient, being cared ... been diagnosed with the deadly virus, officials from the U.S. ... afternoon news conference. The man is receiving intensive care ...
Breaking Medicine News(10 mins):Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2Health News:Long-acting insulin is safer, more effective for patients with Type 1 diabetes 2Health News:Indosoft Announces Q-Suite Support For Sangoma Lyra 2Health News:Law Offices of D.R. Jones Client Wins 4.7 Million Dollar Verdict, Insurance Company Files Motion for a New Trial 2Health News:Law Offices of D.R. Jones Client Wins 4.7 Million Dollar Verdict, Insurance Company Files Motion for a New Trial 3Health News:CDC Confirms First Patient Diagnosed With Ebola in United States 2Health News:CDC Confirms First Patient Diagnosed With Ebola in United States 3
... ... helicopter, DENVER, Oct. 27 ... in the,world, today announced its Products Division has been awarded a contract ... Black Hawk Multi-Mission Medevac Interior Systems. Production has,started and is anticipated to ...
... Journal of Neurodevelopmental Disorders to complement its ... will be available in both online and print ... include both researchers and clinicians interested in an ... of neurodevelopmental disorders. , The Journal of ...
... people who have a positive outlook, lower stress levels, ... income and no chronic health conditions are more likely ... study in the October issue of The ... study of its kind, researchers from Portland State University, ...
... added benefits to improve care and quality ... health conditions-, SAN ANTONIO, Texas, Oct. 27 ... period which begins November 15th, Care,Improvement Plus today ... Plan,(SNP) offerings for chronically ill Medicare beneficiaries in ...
... the Johns Hopkins Bloomberg School of Public Health have ... older Americans to understand patterns of disability and aging. ... National Institutes of Health, is expected to award approximately ... and implement the new survey. The study will include ...
... PHILADELPHIA Edith P. Mitchell, M.D., clinical professor, Department ... Jefferson University and associate director of Diversity Programs for ... with a ,Tree of Life, award from The Wellness ... organization. , The Tree of Life award ...
Cached Medicine News:Health News:Air Methods Receives $17 Million Contract from Sikorsky Aircraft Company 2Health News:Springer adds Journal of Neurodevelopmental Disorders to biomedical journal portfolio 2Health News:Study reveals factors of exceptional health in old age 2Health News:Care Improvement Plus Launches 2009 Benefits in Texas 2Health News:Bloomberg School of Public Health to lead nationwide aging study 2Health News:Jefferson doctor receives Tree of Life award 2Health News:Jefferson doctor receives Tree of Life award 3
Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of CRP in serum....
For the quantitative in vitro determination of Apolipoprotein A-1 in human serum....
For the quantitative determination of apolipoprotein B (apo B) in serum and plasma....
The GGT method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of g-glutamyl transferase activity in serum and plasma...
Medicine Products: